Last reviewed · How we verify
Cisplatin, paclitaxel
Cisplatin and paclitaxel work together as a chemotherapy combination: cisplatin crosslinks DNA to prevent replication, while paclitaxel stabilizes microtubules to disrupt cell division.
Cisplatin and paclitaxel work together as a chemotherapy combination: cisplatin crosslinks DNA to prevent replication, while paclitaxel stabilizes microtubules to disrupt cell division. Used for Advanced or metastatic solid tumors (lung cancer, ovarian cancer, gastric cancer, and others depending on trial design).
At a glance
| Generic name | Cisplatin, paclitaxel |
|---|---|
| Also known as | Platinum-Fluoropyrimidine Regimens (alternative 2a) |
| Sponsor | Karolinska University Hospital |
| Drug class | Chemotherapy combination (platinum agent + taxane) |
| Target | DNA (cisplatin); β-tubulin/microtubules (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that forms covalent bonds with DNA, causing interstrand crosslinks that block DNA replication and transcription, ultimately triggering apoptosis. Paclitaxel is a taxane that binds to β-tubulin and stabilizes microtubules, preventing their depolymerization and disrupting mitotic spindle formation. Together, they provide synergistic cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic solid tumors (lung cancer, ovarian cancer, gastric cancer, and others depending on trial design)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Alopecia
- Mucositis
- Hypersensitivity reaction (paclitaxel)
Key clinical trials
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (PHASE2)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin, paclitaxel CI brief — competitive landscape report
- Cisplatin, paclitaxel updates RSS · CI watch RSS
- Karolinska University Hospital portfolio CI